Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

DA Davidson analyst Gil Luria set a $3,000 12-month price target for Micron (MU), citing a long-lasting supply-demand imbalance in memory chips. Micron's stock has surged 1,500% since April 2023. Luria argues the AI infrastructure build-out creates a structural tailwind, while critics note Micron's lower HBM market share and reliance on conventional DRAM/NAND price increases.

Marvell Technology (MRVL) aims for $70B-$90B revenue by 2031, up from $8.2B in 2026. Its stock trades at 23.81x earnings, below its history and sector. The company designs chips for data centers, with data center sales up 46% YoY to $2.17B in Q2 2027. Management raised fiscal 2028 revenue outlook to $20B, with $18B from data centers.

BofA downgraded Alignment Healthcare (ALHC) to Neutral, cutting its price target to $9.00 from $25.00 due to a drop in Medicare star ratings. ALHC's membership in 4-star or higher plans fell to 25% from 100%, impacting rates. The stock is down 59% over six months. Q2 2026 earnings beat estimates, but revenue missed slightly. Analysts are divided on ALHC's outlook.

BioMarin Pharmaceutical Inc. (BMRN) presented new data at the American Society for Bone and Mineral Research 2026 Annual Meeting, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The data showed encouraging imaging results from a trial evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia.

Lockheed Martin (LMT) secured a contract with the Philippine Department of National Defense for advanced training equipment and services, including a Black Hawk simulator and maintenance trainer. The deal, covering support through 2032, marks the first order for LMT's S-70i Black Hawk training devices. LMT's earnings estimates show a year-over-year improvement of 31.7% for 2026 and 8.44% for 2027, with a forward P/S ratio of 1.40X, below the industry average of 2.07X.

Jazz Pharmaceuticals announced that Samantha Pearce, its Executive Vice President and Chief Commercial Officer, will retire. Her departure is effective upon the appointment of a successor or by June 30, 2027, according to the company. The board will consider both internal and external candidates for the role.